This topic contains a solution. Click here to go to the answer

Author Question: Which of the following is a difference between a skunk works and a new venture division? A) A ... (Read 29 times)

Caiter2013

  • Hero Member
  • *****
  • Posts: 607
Which of the following is a difference between a skunk works and a new venture division?
 
  A) A skunk works is formed for marketing a newly developed product whereas a new venture division is formed for improving the quality of a newly developed product.
  B) A skunk works consists of top-level managers whereas a new venture division consists of low-level managers.
  C) A skunk works is dissolved when the product is brought to market whereas a new venture division assumes full responsibility for the commercialization of the product.
  D) A skunk works is formed for achieving an incremental innovation whereas a new venture division is formed for achieving a quantum innovation.

Question 2

Which of the following is most likely to promote innovation in an organization?
 
  A) adopting a product team structure
  B) increasing vertical differentiation
  C) decreasing the flexibility of the organization
  D) increasing the number of levels in the organizational hierarchy



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

zacnyjessica

  • Sr. Member
  • ****
  • Posts: 345
Answer to Question 1

This is great. Thanks

Answer to Question 2

This is great. Thanks





 

Did you know?

The Romans did not use numerals to indicate fractions but instead used words to indicate parts of a whole.

Did you know?

Women are 50% to 75% more likely than men to experience an adverse drug reaction.

Did you know?

Cutaneous mucormycosis is a rare fungal infection that has been fatal in at least 29% of cases, and in as many as 83% of cases, depending on the patient's health prior to infection. It has occurred often after natural disasters such as tornados, and early treatment is essential.

Did you know?

As many as 28% of hospitalized patients requiring mechanical ventilators to help them breathe (for more than 48 hours) will develop ventilator-associated pneumonia. Current therapy involves intravenous antibiotics, but new antibiotics that can be inhaled (and more directly treat the infection) are being developed.

Did you know?

In Eastern Europe and Russia, interferon is administered intranasally in varied doses for the common cold and influenza. It is claimed that this treatment can lower the risk of infection by as much as 60–70%.

For a complete list of videos, visit our video library